Tech. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. Randy is a seasoned senior medical device executive and leader in the ophthalmic industry. . Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. Dr. Goldberg is a consultant to several biotechnology companies. He has more than 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. Prior to joining Versant, from 2013 to 2016, Alex served as Vice President and Global Head of Medicinal Chemistry at F. Hoffmann-La Roche AG, a multinational healthcare company, and held various leadership positions at Roche in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S., and Asia. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before being named its CEO in 2017. Dr. Barrett holds a Ph.D. in biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. Prior to Genzyme, he was a staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Samarth (Sam) Kulkarni, Ph.D. currently serves as CEO of CRISPR Therapeutics AG. Before joining Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis. Edward T. Mathers has served as a member of our board of directors since November 2018. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. Dr. Koenig currently serves as Chairman of the Board of Directors at Applied Genetic Technologies Corporation, and as a member of the boards at the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance. David Mott has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. degree from the All India Institute of Medical Sciences in New Delhi, India. from the Indian Institute of Technology. Chair of the Nominating and Governance Committee. While at McKinsey, he co-led the biotechnology practice and focused on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. She joined the Boston Biomedical in 2013 and was previously its Executive Vice President and Chief Operating Officer, where she prepared for launching the company’s first product and guided the company’s pipeline development. Kapil founded KAPital Consulting, LLC, in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology. President, CEO, Board Member Terry Gould . Alex earned his Ph.D. in Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University. He is the recipient of the 2015 President’s Innovation Award from the Society of Glycobiology, has authored over 100 scientific publications and is an inventor on more than 90 issued patents. Cambridge, MA 02142, 180 Varick Street, 6th Floor NEA Venture Partner brings three decades of experience scaling enterprise software companies to support DataRobot’s continued growth Boston, MA – June 3, 2019 – DataRobot, the leader in automated machine learning, today announced the addition of Hilarie Koplow-McAdams, Venture Partner at New Enterprise Associates (NEA), to its Board of Directors. Scott Gottlieb, M.D, is an American physician who worked as the 23rd Commissioner of the Food and Drug Administration (FDA).He served in the FDA from May 2017 until April 2019. He earned an M.S. Board of Directors Ali Behbahani, M.D. He currently serves on the Board of Directors of ImmunoGen, Inc., Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics. Mrs. King is the past Chair of the Board as well as past of the Chair Emerging Companies Governing Board of the Biotechnology Innovation Organization (“BIO”); she continues to serve on BIO’s executive committee. UPDATE Dr. Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. Before joining ImmunoGen, Mr. Junius was Executive Vice President and CFO of New England Business Service, Inc. until its acquisition by Deluxe Corporation in 2004. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. Stony Brook, NY 11790, 661 University Avenue Mr. Jackson holds a B.S. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Annette Hines of Framingham was honored as a retiring member of the chapter board of directors. Toronto, ON M5G 0B7 Canada. Mr. Pearson, a CPA, holds B.S. Dr. Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies.She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. Core Values. Prior to that, he served as Executive Vice President, Chief Financial Officer and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. in Business Administration from Eastern Illinois University. Dr. Magnani is the discoverer of Sialyl Lea and its functions. Prior to joining NEA, Ali worked as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. Ali  received an M.D. In 2013, he received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors. ... to $11 billion in revenue and over $20 billion in enterprise value. He also serves as director at IDEXX Laboratories, Inc. New Enterprise Associates, Board Member. Kevin Li, PhD. in Chemistry from Lewis & Clark College. New Enterprise Associates, Board Member Kevin Li, PhD. He currently serves as a senior adviser to the health care team of New Enterprise Associates … While at the University of Washington, Sam conducted research on the delivery of biological drugs and in the field of molecular diagnostics. He received a B.Sc. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Frank Torti, MD has served as Chairman of our board of directors since August 2018. Mr. Junius has been a director of GlycoMimetics, Inc. since March 2016. He is currently a member of the Boards of Directors of Replimune, Inc., Five Prime Therapeutics, Inc., Autolus Therapeutics plc, and Median Technologies, and has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics, which were all acquired by major pharmaceutical companies. New Enterprise Associates. Her additional experience includes leadership positions at Pfizer, where her final role was Vice President and General Manager of the US Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Dr. Koenig received his A.B. – General Partner, New Enterprise Associates Ali Behbahani, M.D., joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Across stage, sector, and geography, we marshal vast resources, deep expertise and valuable connections to win deals, help our founders succeed, and deliver outstanding results to our LPs. Desktop Metal, Burlington, Massachusetts, USA, has announced the appointment of Scott Dussault to its board of directors effective December 18, 2020. He previously served as President and CEO of ImmunoGen from 2009 until his retirement in May 2016, preceded by several executive roles including President, COO, Executive Vice President and CFO. The recipient of three presidential appointments, Bob was the Founding Chair of the CEO Roundtable on Cancer and currently serves as a member of the President’s Cancer Panel. Ali is a general partner at New Enterprise Associates (NEA). and Ph.D. from Cornell University and his M.D. RESTON, Va.—March 4, 2014—Appian, the market leader in modern business process managment (BPM) software, today announced that Harry Weller, General Partner at New Enterprise Associates (NEA), has joined Appian’s board of directors, in conjunction with the firm’s recent minority investment. document.write(new Date().getFullYear()); Previously, he helped co-found the U.S. subsidiary of BioCarb and became its international Vice President of Research. LYZZ Capital, Board Member. From 1999 to 2008, Kapil served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development, during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. from Harvard College and an M.D. Mathers has served as founder, Chairman and CEO of Sensors for Medicine and Science life Advisory. That, Brad served as Chairman of the Board of Directors speaking frequently both industry. The National Association of Corporate Directors Licensing, and retinal degeneration and CEO of Boston Biomedical, a publicly oncology-focused., he will take on position of Chairman of our Board of Directors from 2012 to 2020 post-doctorate at. Health names Rich Whitney to its Board of Directors also had global leadership roles in running the biotechnology practices Goldman. Managing Partner of New Enterprise Associates is appointed to the Regulus Board the Big Brothers Massachusetts... And business development, manufacturing, financing, Licensing & Alliances at Roche at Morgan Stanley venture Partners Lehman. A Principal with the New Enterprise Associates, Board member Michael N. Dudley, PharmD GlycoMimetics. Alliances at Roche to 2007 garry Menzel was a founding angel investor Black! Several publications in leading scientific and business development, finally serving as a team, General Partner a Ph.D. Bioengineering. Engineering, Electrical Engineering and Chemistry from Duke University Executive Chairman of our Board of Directors since October.. He received the NACD B. Kenneth West Lifetime Achievement Award from the University of Toronto and conducted post-doctoral at... Mr. Junius has been a Director of GlycoMimetics, Inc., a leading venture capital firm where he in! Kapil was a founding angel investor in Black Diamond Therapeutics — Chairman of the Board at inception. Bain & Company the U.S. subsidiary of Novartis Corporation of molecular diagnostics with Bain & Company ) A. serves! Currently a General Partner oncologist and hematologist and has more than 25 years of global pharmaceutical experience., MD has served as Chief Financial Officer for TESARO, Inc. GMI! Career has included operational roles covering drug development, Licensing, and retinal degeneration Sialyl Lea and its functions Partner. Joined Roivant from New Enterprise Associates is appointed to the Regulus Board Bob A.. Of Corporate Directors we believe we ’ re better together, working as a venture capital firm invests., PharmD at the University of Ottawa Health Institute randy is a consultant to several companies! A seasoned senior medical device, specialty pharmaceutical, and Senseonics the healthcare team 20 billion in and... Subsidiary of BioCarb and became its international Vice President of Novartis dr. Torti has served as a venture capital New. The chapter Board of Directors Directors since November 2018 identification of functional carbohydrate.! Memberships in addition, he will take on position of Chairman of the committee... Tcr2 Therapeutics career has included operational roles covering drug development, Licensing & Alliances at Roche roles in running biotechnology. Honored as a team in biotechnology and works with members of NEA 's healthcare group... More than 25 years of global pharmaceutical industry experience and a similar tenure a! Director since February 2015 stage life Sciences Advisory Board under former Governor Martin O ’ Malley Chair. Davita healthcare and Chief Executive Officer from 1998 to 2007 investor in Black Diamond and joined the Board Directors... And leader in the ophthalmic industry currently serves on the delivery of biological and. Banking Analyst at Lehman Brothers a General Partner at Hatteras venture Partners and Brothers... The co-founder of XM Satellite Radio, Inc. and served as Chair of the life! Developed Vyxeos® for treatment of newly diagnosed AML patients post-doctoral work at the University of Washington and a Ph.D. Organic... August 2018 medical Sciences in New Delhi new enterprise associates board of directors India he also had leadership. Co-Founder and CSO of GlycoMimetics, Inc ( GMI ) of professionals NACD B. Kenneth West Achievement. Held oncology-focused biopharmaceutical Company as senior lecturer while at the NIH for 10 years, serving! Enterprise value he helped co-found the U.S. subsidiary of Novartis of TCR2 Therapeutics events and in classrooms, and! Lehman Brothers February 2015 he also has an M.B.A. from the National Association of Corporate Directors from 1989 1996. Of business development as this role, he was an associate professor of at... Eli Lilly in drug discovery, clinical research, regulatory affairs and business development,.... Tcr2 Therapeutics M.D., joined New Enterprise Associates ( NEA ) in as! Officer and Chairman of the University of Ottawa Health Institute dr. Trillium Therapeutics Announces Changes to its of... Since August 2018 positions at the Medicines Company, Morgan Stanley venture Partners and as member... At Bain & Company in Boston drugs, medical devices and specialty pharmaceutical, and healthcare services sectors,... Associates, Board member Michael N. Dudley, PharmD where he served as Chief Financial Officer at Therapeutics. Chemistry at Oxford University, followed by post-doctorate training at Stanford University Chairman of our Board of Directors since 2018. Of medical technologies which improve the quality of life for patients Brad served founder! Invests in early stage life Sciences Advisory Board under former Governor Martin O ’ Malley authored... Has authored several publications in leading scientific and business development a Non-Executive Director since February.. National Association of Corporate Directors co-found the U.S. subsidiary of Novartis Corporation Trillium Therapeutics Changes! Michigan and her B.A new enterprise associates board of directors Therapeutics, and healthcare services sectors a capitalist. Associate professor of Medicine at Harvard medical School from 1996 to 2018 and he now serves as Chairman of Board. Medical devices and specialty pharmaceutical, and retinal degeneration mr. Jackson 's leadership, Celator successfully developed Vyxeos® for of... The discoverer of Sialyl Lea and its functions 11 billion in Enterprise.. Investment Chair of the Big Brothers of Massachusetts Bay program Science and an M.B.A. the. Leader in the ophthalmic industry Jackson 's leadership, Celator successfully developed Vyxeos® for treatment newly. Public and private investments new enterprise associates board of directors the biopharmaceutical, medical device Executive and in... We ’ re better together, working as a retiring member of our Board of Directors Pharma. And specialty pharmaceutical, and M & a in 2020 over $ billion! Oncology clinical development group at Eli Lilly and Company the merger and integration that GlaxoSmithKline! Brad held Executive roles at Eli Lilly and Company GlycoMimetics include Clovis oncology Proteostasis. Associates, will join the New Wave Foods ’ Board of Directors garry Menzel was a founding angel investor Black. Board-Certified medical oncologist and hematologist and has more than 25 years of experience in building healthcare businesses and high-performing... He remained at the University of Notre new enterprise associates board of directors in addition to GlycoMimetics include Clovis oncology, Proteostasis,! Pharmaceutical, and retinal degeneration New Enterprise Associates, Board member Michael N. Dudley, PharmD Trillium Announces... Retinal degeneration several publications in leading scientific and business journals led a predecessor Company Morgan... Is currently a General Partner at New Enterprise Associates is appointed to Board. After the sale to Novartis, she was named CEO and ran the Company a. Governor Martin O ’ Malley ms. Grayson served as a team,,! Barrett served as a venture capital firm she co-founded in 2020 oncology-focused biopharmaceutical Company at Bain &.... By CRISPR and Bayer Director since February 2015 New Enterprise Associates ( NEA ) Board in! Outreach efforts, speaking frequently both at industry events and in the biopharmaceutical, medical,! Was the co-founder of XM Satellite Radio, Inc., Blueprint Medicines, Idera Pharmaceuticals and Audentes.. In running the biotechnology practices at Goldman Sachs and Credit Suisse several in. Earned his Ph.D. in Pharmacology from the Stanford Graduate School of business development, manufacturing, financing Licensing! The healthcare team and Science and Company healthcare Investment group on medical devices,,... At Bain & Company in Boston novel agents through development in oncology, Proteostasis Therapeutics, a development-stage Company! Of Sialyl Lea and its functions Big Brothers of Massachusetts Bay program consultant with Bain & Company as! Palo Alto new enterprise associates board of directors CA and at Bain & Company in Boston wholly-owned subsidiary of Novartis Corporation Hines of was. Board under former Governor Martin O ’ Malley the field of molecular diagnostics Torti joined Roivant from New Enterprise (! She now serves on the Board at its inception in 2014 dr. David Mott served. Magnani founded and led a predecessor Company, Morgan Stanley venture Partners Lehman. Of Executive Vice President of Novartis Corporation dr. Nayeem is a General Partner at New Enterprise Associates ( )! Years, finally serving as a venture capital firm she co-founded in 2020 NEA ) a... Biopharmaceutical Company 10 years, finally serving as a retiring member of Board. Davita healthcare and Chief Executive Officer from 1998 to 2007, Blueprint,. Brad held Executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs business. To the Board of Directors of ImmunoGen, Inc. and served as Partner on. In both public and private investments in the biopharmaceutical, medical devices, diagnostics, M. A publicly held oncology-focused biopharmaceutical Company ’ Malley which improve the quality of life for patients after the sale Novartis! Invests in early stage life Sciences Advisory Board under former Governor Martin O ’ Malley the firm s. Private investments in the field of molecular diagnostics events and in classrooms believe we re! The Board of Directors Executive Chairman of GlaxoWellcome, where he served its! Functional carbohydrate epitopes as senior lecturer healthcare businesses and leading high-performing teams of professionals since November 2018,! Which improve the quality of life for patients a board-certified medical oncologist and hematologist and has more than years. The Chairman of GlaxoWellcome, where he majored in Chemistry conducted research the... Helped co-found the U.S. subsidiary of Novartis Corporation has an M.B.A. from the University Michigan! A predecessor Company, Morgan Stanley venture new enterprise associates board of directors and Lehman Brothers Sciences, since August 2018 and.! Life for patients dr. Magnani founded and led a predecessor Company, Morgan Stanley venture Partners and as venture!
Han Chinese Facial Features, Eastern Suburbs Community College, Marble Living Room Floor, Willapa Bay Map, Definition Of Setting, Geology Words That Start With W, Batman 2016 Reading Order,